You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Myelodysplastic Syndromes

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed / Refractory MDS Trial (NCR300)

Not yet recruiting
  • Relapsed / Refractory Myelodysplastic Syndromes
  • (no location specified)
May 7, 2022

AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)

Not yet recruiting
  • AML/MDS
  • +2 more
  • (no location specified)
Aug 14, 2023

Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Duarte, California
  • +3 more
Nov 21, 2023

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023

MDS (MDS) Trial in United States (Panobinostat)

Terminated
Has Results
  • Myelodysplastic Syndromes (MDS)
  • Fort Myers, Florida
  • +6 more
Nov 18, 2021

Acute Myeloid Leukemia, MDS Trial in Rochester, Houston (CTX-712)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Rochester, Minnesota
  • +1 more
Feb 15, 2023

Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

Available
  • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Magrolimab
  • (no location specified)
Jan 18, 2023

MDS Trial (Roxadustat in combination with retinoic acid)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Roxadustat in combination with retinoic acid
  • (no location specified)
Aug 26, 2023

Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +2 more
  • VEN+AZA+Modified BUCY
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 10, 2023

MDS Trial in Beijing (Roxadustat, Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
    Peking union medical college hospital
Aug 17, 2023

Recurrent/Refractory Acute Myeloid Leukemia, MDS Trial in ChengDu (TQB2618 injection azacitidine, AZA decitabine, DAC)

Recruiting
  • Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
  • TQB2618 injection azacitidine, AZA decitabine, DAC
  • ChengDu, Sichuan, China
    West China Hospital of Sichuan University
Jun 16, 2022

Low Risk MDS Trial (R906289 Monosodium (R289 Na))

Not yet recruiting
  • Low Risk Myelodysplastic Syndromes
  • R906289 Monosodium (R289 Na)
  • (no location specified)
Jul 22, 2022

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Myelodysplastic/Myeloproliferative Tumor, Steroid Refractory GVHD, Allogeneic Hematopoietic Cell Transplant Trial in Toronto

Completed
  • Myelodysplastic/Myeloproliferative Neoplasm
  • +2 more
  • Decidual stromal cells (DSC)
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Boston (BXCL701)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-2
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 26, 2023

Myelodysplastic Syndrome Trial in Nagoya, Fukuoka, Tokyo (SyB L-1101)

Completed
Has Results
  • Myelodysplastic Syndrome
  • SyB L-1101
  • Nagoya, Aichi, Japan
  • +2 more
Nov 14, 2022

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Refractory MDS Patients

Active, not recruiting
  • Myelodysplastic Syndromes
    • Stanford, California
      Stanford MDS Center
    Aug 1, 2022

    Myelodysplastic Syndrome Trial in Japan (SyB C-1101)

    Completed
    Has Results
    • Myelodysplastic Syndrome
    • SyB C-1101
    • Nagoya, Aichi, Japan
    • +3 more
    Nov 14, 2022

    Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

    Recruiting
    • Leukemia
    • +3 more
    • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
    • Amsterdam, Netherlands
    • +4 more
    Jan 4, 2023

    Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,

    Recruiting
    • Stem Cell Transplant Complications
    • +4 more
    • Radiation
    • +7 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jan 19, 2023

    Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, MDS Trial in Cleveland (CPX-351)

    Recruiting
    • Refractory Acute Myeloid Leukemia
    • +2 more
    • Cleveland, Ohio
      Cleveland Clinic, Case Comprehensive Cancer Center
    Mar 15, 2022

    Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia Trial in United States

    Active, not recruiting
    • Recurrent Acute Myeloid Leukemia
    • +3 more
    • Tampa, Florida
    • +5 more
    Nov 18, 2022